Objective: To measure HPV vaccine acceptance in diverse Mexican adult popula-tions, taking into account HIV status.
Materials And Methods: A total of 1 329 men and women, with and without HIV, participated in one of three intervention studies, offering HPV vaccination, carried out in the states of Morelos, Tlaxcala and Mexico City; either the bivalent (Morelos n=103, Tlaxcala n=127) or quadrivalent HPV-vaccine (Mexico City n=1 099) was offered.
Results: HPV vaccine was accepted by 80.3% of participants; acceptance was higher in people living with HIV than those without (84.4 vs. 78%, p=0.004). Women had greater HPV infection knowledge (p<0.0001) than men and slightly higher (p=0.4) vaccine acceptance. The main reason for vaccine non-acceptance among HIV-positive participants was their doctor recommended they not get vaccinated.
Conclusions: Acceptance of HPV-vaccine was high in men and women regardless of HIV status. Even higher rates of acceptability may be achieved by educating healthcare providers to recommend HPV vaccine to their patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21149/10182 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Knowledge, attitude, practices, and associated factors toward cervical cancer among female health sciences students of Addis Ababa University, Addis Ababa, Ethiopia.
Ther Adv Vaccines Immunother
January 2025
Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Cervical cancer is the most common cancer in women worldwide. Early screening and vaccination can prevent cervical cancer; however, the low levels of knowledge, attitude, and practice among the young can contribute to the high prevalence of cervical cancer.
Objective: This study aimed to assess the level of knowledge, attitude, and practice of cervical cancer and associated factors among female Health Sciences students of the College of Health Sciences at Addis Ababa University.
Adenoviral Therapy for Cervical Cancer: From Targeted Modification to Immunotherapy.
Anticancer Agents Med Chem
January 2025
Department of Gynecology, Lanzhou University Second Hospital Lanzhou University, Lanzhou, 730030, China.
Cervical cancer is a significant global health threat, ranking as the fourth most common malignancy among women and resulting in over 300,000 deaths annually. Although screening and vaccination initiatives have led to a decline in incidence rates, treatment options for advanced or recurrent cervical cancer remain inadequate, often proving ineffective and costly. In this context, adenoviral therapy has emerged as a promising strategy to enhance therapeutic outcomes.
View Article and Find Full Text PDFGlobal research hotspots and trends in DNA vaccine research: A bibliometric and visualization study from 2014 to 2024.
Hum Vaccin Immunother
December 2025
Department of Thyroid and Breast Surgery, Jining NO. 1 People' Hospital, Jining, China.
This bibliometric and visualization study provides a comprehensive analysis of global research hotspots and trends in DNA vaccine research from 2014 to 2024. By employing data sourced from the Web of Science Core Collection, we identified a total of 3,600 articles. Our analysis reveals a declining trend in annual publications.
View Article and Find Full Text PDFKnowledge and attitudes about human papillomavirus infection and prevention methods among medical science students in Novi Sad, Serbia: a cross-sectional study.
BMC Public Health
January 2025
Department of Pharmacology, Toxicology and Clinical Pharmacology, Faculty of Medicine Novi Sad, University of Novi Sad, Novi Sad, Serbia.
Background: It is estimated that more than 80% of people are infected with human papilloma virus (HPV) at some point in their lives. Knowledge about HPV infection and methods of its prevention is important for society as a whole. Medical students as future healthcare workers must be thoroughly informed about HPV infection in order to properly participate in the promotion of its prevention.
View Article and Find Full Text PDFBackground: Persistent infection with human papillomavirus (HPV) is associated with most cervical and anal cancer cases and a large fraction of other anogenital and oropharyngeal cancers. The prophylactic HPV vaccines are known to prevent HPV infections and HPV-associated disease, although there is evidence of reduced response to the HPV vaccination among individuals living with HIV. Prior studies among individuals without HIV suggest that a single HPV vaccine dose induces humoral immune responses that, while lower than those induced by two or three doses, still confer protection against HPV infection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!